Antifungal Drugs Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Antifungal Drugs Market Size Analysis and Top Companies

The global antifungal drugs market size is estimated at to hit around USD 23.68 billion by 2033 from USD 17.39 billion in 2024, with a CAGR of 3.49% from 2024 to 2033. The top companies operating in the antifungal drugs market are Pfizer, Inc., Novartis AG, Sanofi, GlaxoSmithKline plc, Bayer AG, Glenmark, Abbott, Astellas Pharma, Inc., and Enzon Pharmaceuticals, Inc.

Market Scope

Antifungal Drugs Market Companies

• Pfizer, Inc.
• Novartis AG
• Sanofi
• GlaxoSmithKline plc
• Bayer AG
• Glenmark
• Abbott
• AstellasPharma, Inc.
• Enzon Pharmaceuticals, Inc.

Recent Developments

• In June 2021, Posaconazole Gastro, a new medication, was introduced, according to Mankind Pharma. These tablets are used to cure black fungus; they are resistant ones. It has been discovered to be a preferred medicine for disease management that is safer and more effective. The Drug Controller General of India (DCGI) has approved this medication.
• In June 2021, Posaconazole, a novel triazole antifungal medicine from Cadila Pharmaceuticals, became effective against various invasive fungal disorders. The medication was also suggested as a backup treatment for mucormycosis.
• In June 2021, Brexafemme's approval by the US Food and Drug Administration to treat vaginal yeast infections was announced by Scynexis.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344